Pharming Group NV - ESG Rating & Company Profile powered by AI
This ESG rating for Pharming Group NV indicates the company's reporting of the UN SDGs. This report of Pharming Group NV leverages information from across the web as well as from public documents by Pharming Group NV. Other corporations in the scoring peer group for Pharming Group NV are displayedin the table.
Pharming Group NV in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 4.9; made up of an environmental score of 2.0, social score of 4.8 and governance score of 8.0.
4.9
Medium ImpactEnvironmental
Social
Governance
Peer Group Comparison
| Rank | Company | SDG Transparency Score ⓘ | Performance |
|---|---|---|---|
| 1 | Caladrius Biosciences Inc | 8.0 | High |
| 1 | Can Fite Biopharma Ltd | 8.0 | High |
| 744 | Sopharma AD | 5.0 | High |
| 744 | vTv Therapeutics Inc | 5.0 | High |
| 764 | Pharming Group NV | 4.9 | High |
| 764 | BetterLife Pharma Inc | 4.9 | High |
| 764 | Acerus Pharmaceuticals Corporation | 4.9 | High |
| ... | ... | ... | |
| 1970 | Zyden Gentec Ltd | 0.0 | Low |
| 1970 | iNtRON Biotechnology Inc | 0.0 | Low |
| ... | ... | ... |
Frequently Asked Questions
Does Pharming Group NV have an accelerator or VC vehicle to help deliver innovation?
Sign up for free to unlockDoes Pharming Group NV disclose current and historical energy intensity?
Sign up for free to unlockDoes Pharming Group NV report the average age of the workforce?
Sign up for free to unlockDoes Pharming Group NV reference operational or capital allocation in relation to climate change?
Sign up for free to unlockDoes Pharming Group NV disclose its ethnicity pay gap?
Sign up for free to unlockDoes Pharming Group NV disclose cybersecurity risks?
Sign up for free to unlockDoes Pharming Group NV offer flexible work?
Sign up for free to unlockDoes Pharming Group NV have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Sign up for free to unlockDoes Pharming Group NV disclose the number of employees in R&D functions?
Sign up for free to unlockDoes Pharming Group NV conduct supply chain audits?
Sign up for free to unlockDoes Pharming Group NV disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Sign up for free to unlockIs there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Sign up for free to unlockDoes Pharming Group NV conduct 360 degree staff reviews?
Sign up for free to unlockDoes Pharming Group NV disclose the individual responsible for D&I?
Sign up for free to unlockDoes Pharming Group NV disclose current and historical air emissions?
Sign up for free to unlockIs there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Sign up for free to unlockIs executive remuneration linked to climate performance?
Sign up for free to unlockDoes the Board describe its role in the oversight of climate-related risks and opportunities?
Sign up for free to unlockDoes Pharming Group NV disclose current and / or historical scope 2 emissions?
Sign up for free to unlockDoes Pharming Group NV disclose water use targets?
Sign up for free to unlockDoes Pharming Group NV have careers partnerships with academic institutions?
Sign up for free to unlockDid Pharming Group NV have a product recall in the last two years?
Sign up for free to unlockDoes Pharming Group NV disclose incidents of discrimination?
Sign up for free to unlockDoes Pharming Group NV allow for Work Councils/Collective Agreements to be formed?
Sign up for free to unlockHas Pharming Group NV issued a profit warning in the past 24 months?
Sign up for free to unlockDoes Pharming Group NV disclose parental leave metrics?
Sign up for free to unlockDoes Pharming Group NV disclose climate scenario or pathway analysis?
Sign up for free to unlockDoes Pharming Group NV disclose current and / or historical scope 1 emissions?
Sign up for free to unlockAre Operating Expesnses linked to emissions reduction?
Sign up for free to unlockDoes Pharming Group NV disclose the pay ratio of women to men?
Sign up for free to unlockDoes Pharming Group NV support suppliers with sustainability related research and development?
Sign up for free to unlockDoes Pharming Group NV disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Sign up for free to unlockDoes Pharming Group NV reflect climate-related risks in its financial statements?
Sign up for free to unlockIs there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Sign up for free to unlockIs Pharming Group NV involved in embryonic stem cell research?
Sign up for free to unlockDoes Pharming Group NV disclose GHG and Air Emissions intensity?
Sign up for free to unlockDoes Pharming Group NV disclose its waste policy?
Sign up for free to unlockDoes Pharming Group NV report according to TCFD requirements?
Sign up for free to unlockDoes Pharming Group NV disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Sign up for free to unlockDoes Pharming Group NV disclose energy use targets?
Sign up for free to unlockDoes Pharming Group NV disclose its Renewable Energy targets?
Subscription requiredAre emissions metrics verified by STBi?
Subscription requiredDoes Pharming Group NV have a policy relating to cyber security?
Sign up for free to unlockHave a different question?
Potential Risks for Pharming Group NV
These potential risks are based on the size, segment and geographies of the company.
Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.